Press Releases

07.11.2016

• Capital increase and convertible bond with gross proceeds of presumably €16.1 million • Further implementation of the “Next Level” corporate strategy • Advancement of the four clinical studies with the lead product lefitolimod (MGN1703)...

12.09.2016

The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today first preliminary data on its EnanDIM® technology in a murine tumor model.

   

Displaying results 1 bis 7 von 19

Page 1

Page 2

Page 3

next

   

Share Subscription Facility with US investor GCF

Further Information

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com